Pixxoscan is intended for contrast enhancement in cranial and spinal MRI. Credit: Business Wire / GE HealthCare.

GE HealthCare has expanded its magnetic resonance imaging (MRI) contrast agent portfolio with the launch of Pixxoscan (gadobutrol).

Designed to enable the visualisation of abnormal structures or lesions, the new MRI agent helps differentiate between healthy and pathological tissue.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Pixxoscan is intended for contrast enhancement in cranial and spinal MRI as well as magnetic resonance angiography.

It is suitable for individuals across all age groups including adults, adolescents and children (including term neonates).

Pixxoscan is also recommended for whole-body imaging in individuals suspected to have focal lesions to determine whether they are benign or malignant.

GE HealthCare pharmaceutical diagnostics chief medical officer Mark Hibberd said: “This extension to our portfolio means we will be able to offer two leading macrocyclic molecules – Clariscan (gadoteric acid) and Pixxoscan (gadobutrol) – to our customers in a number of European countries, offering radiology departments even more choice to suit their diagnostic needs.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pixxoscan was assessed through a regulatory decentralised procedure (DCP) and already obtained marketing authorisation in Austria. DCP is a process to gain marketing authorisation in more than one European Union member state.

The company is currently awaiting approval for Pixxoscan and plans to introduce it in several European countries this year.

The company’s MRI contrast media portfolio also includes macrocyclic Clariscan (gadoteric acid) and Rapiscan.

Rapiscan is used in stress cardiac MR examinations to help diagnose coronary artery disease. For patients who are unable to exercise, it serves as a viable alternative used to simulate the same effect.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact